<DOC>
	<DOCNO>NCT02706392</DOCNO>
	<brief_summary>This phase I trial study side effect best dose genetically modify T-cell therapy treat patient receptor tyrosine kinase-like orphan receptor 1 positive ( ROR1+ ) chronic lymphocytic leukemia ( CLL ) , mantle cell lymphoma ( MCL ) , acute lymphoblastic leukemia ( ALL ) , stage IV non-small cell lung cancer ( NSCLC ) , triple negative breast cancer ( TNBC ) spread place body usually cure controlled treatment ( advanced ) . Genetically modified therapy , ROR1 specific chimeric antigen receptor ( CAR ) T-cells , take patient 's blood , modify laboratory specifically may kill cancer cell protein call ROR1 surface , safely give back patient conventional therapy . The `` genetically modify '' T-cells gene add laboratory make recognize ROR1 .</brief_summary>
	<brief_title>Genetically Modified T-Cell Therapy Treating Patients With Advanced ROR1+ Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety adoptive T cell therapy use ex vivo expand autologous cluster differentiation ( CD ) 8+ CD4+ ROR1 CAR-T cell patient advance ROR1+ hematologic ( Cohort A ) epithelial ( Cohort B ) malignancy . SECONDARY OBJECTIVES : I . To determine duration vivo persistence adoptively transfer T cell , phenotype persist T cell . II . To determine traffic adoptively transfer T cell traffic bone marrow tumor site function vivo . III . To determine preliminary antitumor activity adoptive transfer ROR1 CAR-T cell patient measurable tumor burden prior T cell transfer . OUTLINE : This phase I , dose escalation study ROR1 CAR-specific autologous T-lymphocytes follow phase II study . Patients receive chemotherapy comprise fludarabine phosphate cyclophosphamide determine refer physician consultation protocol principal investigator ( PI ) . Beginning within 36-96 hour completion lymphodepleting chemotherapy , patient receive ROR1 CAR-specific autologous T-lymphocytes intravenously ( IV ) 20-30 minute . Patients may receive second infusion ROR1 CAR-specific autologous T-lymphocytes without additional cytoreductive therapy ( receive high cell dose ) next high dose level persistent disease , toxicity attribute first infusion , patient least 21 day first T cell infusion . After completion study treatment , patient follow least 15 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA FOR PATIENTS WITH CLL , MCL OR ALL ( COHORT A ) CLL beyond first remission fail combination chemoimmunotherapy regimens contain purine analogue antiCD20 antibody , fail tyrosine kinase phosphatidylinositol 3 ( PI3 ) kinase inhibitor , eligible decline therapy ; patient fludarabine refractory disease eligible Mantle cell lymphoma patient beyond first remission previously treat chemoimmunotherapy ; patient relapse follow autologous hematopoietic cell transplant ( HCT ) eligible ALL patient relapse residual disease follow treatment curative intent ; ALL patient must ROR1 express &gt; 90 % leukemia blast eligible Confirmation diagnosis internal pathology review initial subsequent biopsy pathologic material Fred Hutchinson Cancer Research Center ( FHCRC ) /Seattle Cancer Care Alliance ( SCCA ) Evidence ROR1 expression immunohistochemistry flow cytometry prior current tumor specimen Karnofsky performance status &gt; = 70 % Negative pregnancy test woman childbearing potential ; subject childbearing potential surgically sterilize free menses &gt; 1 year Fertile male female patient must willing use contraceptive method , , least two month T cell infusion Ability understand provide inform consent INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Patients stage IV nonsmall cell lung cancer treat least one line prior therapy decline conventional therapy INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Patients know epidermal growth factor receptor ( EGFR ) anaplastic lymphoma kinase ( ALK ) mutation must treat least one line molecularly target therapy ( e.g. , erlotinib , crizotinib ) INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Patients must measurable disease least one criterion : Extra skeletal disease accurately measure least one dimension &gt; = 10 mm conventional compute tomography ( CT ) technique define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Skeletal boneonly disease measurable fludeoxyglucose F 18 ( FDG ) positron emission tomography ( PET ) image INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : ROR1 expression &gt; 20 % primary tumor metastasis immunohistochemistry ( IHC ) INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Karnofsky performance status &gt; = 70 % INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Patients must chemotherapy minimum 3 week prior start treatment ; target therapy must stop least 3 day prior start lymphodepletion INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Negative pregnancy test woman childbearing potential ; subject childbearing potential surgically sterilize free menses &gt; 1 year INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Fertile male female patient must willing use contraceptive method , least two month T cell infusion INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Ability understand provide inform consent INCLUSION CRITERIA FOR TNBC INCLUSION CRITERIA FOR TNBC : Histologically confirm diagnosis metastatic TNBC ; i.e . breast cancer estrogen receptor ( ER ) negative ( = &lt; 10 % ) , progesterone receptor ( PR ) negative ( = &lt; 10 % ) , human epidermal growth factor receptor 2 ( HER2 ) negative ( 0 1+ immunohistochemistry negative gene amplification fluorescence situ hybridization [ FISH ] ) INCLUSION CRITERIA FOR TNBC : Patients must measurable disease least one criterion : Extra skeletal disease accurately measure least one dimension &gt; = 10 mm conventional CT technique define RECIST 1.1 Skeletal boneonly disease measurable FDG PET image INCLUSION CRITERIA FOR TNBC : Patients must receive standard adjuvant , neoadjuvant , and/or metastatic chemotherapy per National Comprehensive Cancer Network ( NCCN ) institutional practice ; maximum number prior systemic treatment regimens INCLUSION CRITERIA FOR TNBC : Patients may receive agent protect skeletal related complication zolendronic acid denosumab INCLUSION CRITERIA FOR TNBC : ROR1 expression &gt; 20 % primary tumor metastasis IHC INCLUSION CRITERIA FOR TNBC : Karnofsky performance status &gt; = 70 % INCLUSION CRITERIA FOR TNBC : Patients must chemotherapy minimum 3 week prior plan leukapheresis INCLUSION CRITERIA FOR TNBC : Negative pregnancy test woman childbearing potential ; subject childbearing potential surgically sterilize free menses &gt; 1 year INCLUSION CRITERIA FOR TNBC : Fertile male female patient must willing use contraceptive method , least two month T cell infusion INCLUSION CRITERIA FOR TNBC : Ability understand provide inform consent EXCLUSION CRITERIA FOR PATIENTS WITH CLL , MCL , OR ALL ( COHORT A ) Treatment investigational agent ( ) within 30 day plan lymphodepletion Patients require ongoing daily corticosteroid therapy dose &gt; 15 mg prednisone per day ( equivalent ) ; pulse corticosteroid use disease control acceptable Active autoimmune disease require immunosuppressive therapy Serum creatinine &gt; 2.5 mg/dL Serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 5 x upper limit normal Bilirubin &gt; 3.0 mg/dL Patients clinically significant pulmonary dysfunction , determine medical history physical exam undergo pulmonary function testing ; force expiratory volume 1 second ( FEV1 ) &lt; 2.0 L diffusion capacity lung carbon monoxide ( DLCO ) ( correct ) &lt; 40 % exclude Significant cardiovascular abnormality define one following : congestive heart failure , clinically significant hypotension , symptomatic coronary artery disease , document ejection fraction &lt; 45 % ; patient ejection fraction ( EF ) 4549 % must receive clearance cardiologist eligible trial Patients human immunodeficiency virus ( HIV ) seropositive Uncontrolled active infection ( bacterial , viral , fungal , mycobacterial ) respond treatment intravenous antibiotic , antiviral antifungal agent , longterm treatment oral agent Anticipated survival &lt; 3 month Women breastfeed Patients contraindication cyclophosphamide chemotherapy Known additional malignancy progress require active treatment ; exception include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy Active central nervous system ( CNS ) metastases and/or carcinomatous meningitis ; subject previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior enrollment neurologic symptom return baseline ) , evidence new enlarge brain metastasis EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Absolute neutrophil count ( ANC ) &lt; 1000/mm^3 EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Hemoglobin ( Hgb ) &lt; 9 mg/dl ( transfusion permit achieve ) EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Platelet count &lt; 75,000/mm^3 EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Treatment investigational agent ( ) within 30 day plan lymphodepletion EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Patients require ongoing daily corticosteroid therapy dose &gt; 15 mg prednisone per day ( equivalent ) ; pulse corticosteroid use disease control acceptable EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Active autoimmune disease require immunosuppressive therapy EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Serum creatinine &gt; 2.5 mg/dL EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : SGOT &gt; 5 x upper limit normal EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : bilirubin &gt; 3.0 mg/dL EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Patients clinically significant pulmonary dysfunction , determine medical history physical exam undergo pulmonary function test ; FEV1 &lt; 2.0 L DLCO ( correct ) &lt; 40 % exclude EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Significant cardiovascular abnormality define one following : congestive heart failure , clinically significant hypotension , symptomatic coronary artery disease , document ejection fraction &lt; 45 % ; patient EF 4549 % must receive clearance cardiologist eligible trial EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Patients HIV seropositive EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Uncontrolled active infection ( bacterial , viral , fungal , mycobacterial ) respond treatment intravenous antibiotic , antiviral antifungal agent , longterm treatment oral agent EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Women breastfeed EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Anticipated survival &lt; 3 month EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Patients contraindication cyclophosphamide chemotherapy EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Known additional malignancy progress require active treatment ; exception include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC ( COHORT B ) : Active central nervous system ( CNS ) metastases and/or carcinomatous meningitis ; subject previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior enrollment neurologic symptom return baseline ) , evidence new enlarge brain metastasis EXCLUSION CRITERIA FOR TNBC EXCLUSION CRITERIA FOR TNBC : ANC &lt; 1000/mm^3 Hgb &lt; 9 mg/dl ( transfusion permit achieve ) EXCLUSION CRITERIA FOR TNBC : Platelet count &lt; 75,000/mm^3 EXCLUSION CRITERIA FOR TNBC : Treatment investigational agent ( ) within 30 day plan lymphodepletion EXCLUSION CRITERIA FOR TNBC : Patients require ongoing daily corticosteroid therapy dose &gt; 15 mg prednisone per day ( equivalent ) ; pulse corticosteroid use disease control acceptable EXCLUSION CRITERIA FOR TNBC : Active autoimmune disease require immunosuppressive therapy EXCLUSION CRITERIA FOR TNBC : Serum creatinine &gt; 2.5 mg/dL EXCLUSION CRITERIA FOR TNBC : SGOT &gt; 5 x upper limit normal EXCLUSION CRITERIA FOR TNBC : Bilirubin &gt; 3.0 mg/dL EXCLUSION CRITERIA FOR TNBC : Patients clinically significant pulmonary dysfunction , determine medical history physical exam undergo pulmonary function test ; FEV1 &lt; 2.0 L DLCO ( correct ) &lt; 40 % exclude EXCLUSION CRITERIA FOR TNBC : Significant cardiovascular abnormality define one following : congestive heart failure , clinically significant hypotension , symptomatic coronary artery disease document ejection fraction &lt; 45 % ; patient EF 4549 % must receive clearance cardiologist eligible trial EXCLUSION CRITERIA FOR TNBC : Patients HIV seropositive EXCLUSION CRITERIA FOR TNBC : Uncontrolled active infection ( bacterial , viral , fungal , mycobacterial ) respond treatment intravenous antibiotic , antiviral antifungal agent , longterm treatment oral agent EXCLUSION CRITERIA FOR TNBC : Anticipated survival &lt; 3 month EXCLUSION CRITERIA FOR TNBC : Breastfeeding woman EXCLUSION CRITERIA FOR TNBC : patient contraindication cyclophosphamide chemotherapy EXCLUSION CRITERIA FOR TNBC : Has know additional malignancy progress require active treatment ; exception include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy EXCLUSION CRITERIA FOR TNBC : Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis ; subject previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior enrollment neurologic symptom return baseline ) evidence new enlarge brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>